Aelis Farma Announces its 2023 Financial Calendar streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AEF0217 is being developed as the first treatment for cognitive deficits caused by a hyperactivity of the CB1 receptor, the first indication being those linked to Down syndrome (Trisomy 21), which
Pier Vincenzo Piazza has won in the "Scale-Up" category for France's Nouvelle Aquitaine region Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage
Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today
H1 2022 marked by the start of recruitment for the phase 2b study with AEF0117 for the treatment of cannabis addiction Solid cash position at €39.8 million as of June 30, 2022, including the